No positive effect of oral magnesium supplementation in the decreases of inflammation in subjects with prediabetes: A pilot study

Magnesium Research

Volumn 25, Issue 3, 2012, Pages 140-146

  Simental Mendía, Luis E ^a,b   Rodríguez Morán, Martha ^a,b   Reyes Romero, Miguel A ^c   Guerrero Romero, Fernando ^a,b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b The Research Group on Diabetes   (Mexico)

^c Polytechnic University of Durango   (Mexico)

Author keywords

Inflammation; Magnesium; Prediabetes

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; MAGNESIUM; MAGNESIUM CHLORIDE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; HYPOMAGNESEMIA; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATION; MALE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SUPPLEMENTATION; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; AGED; C-REACTIVE PROTEIN; DIETARY SUPPLEMENTS; FEMALE; HUMANS; HYPERCALCIURIA; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-6; MAGNESIUM; MALE; MIDDLE AGED; NEPHROCALCINOSIS; PILOT PROJECTS; PREDIABETIC STATE; RENAL TUBULAR TRANSPORT, INBORN ERRORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84868144213     PISSN: 09531424     EISSN: 19524021     Source Type: Journal    
DOI: 10.1684/mrh.2012.0322     Document Type: Article

References (35)

1. Paolisso G, Scheen A, D'Onofrio F, Lefebvre P. Magnesium and glucose homeostasis. Diabetologia 1990; 33: 511-514.
2. Paolisso G, Barbagallo M. Hypertension, diabetes mellitus, and insulin resistance: the role of intracellular magnesium. Am J Hypertens 1997; 10: 346-355.
3. Takaya J, Higashino H, Kobayashi Y. Intracellular magnesium and insulin resistance. Magnes Res 2004; 17: 126-136.
4. Saris NE, Mervaala E, Karppanen H, Khawaja JA, Lewenstam A. Magnesium: an update on physiological, clinical, and analytical aspects. Clinica Chimica Acta 2000; 294: 1-26.
5. Barbagallo M, Gupta RK, Bardicef M, Resnick LM. Altered ionic effects of insulin in hypertension role of basal ion levels in determining cellular responsiveness. J Clin Endocrinol Metab 1997; 82: 1761-1765.
6. Haffner SM, Miettinen H. Insulin resistance implications for type II diabetes mellitus and coronary heart disease. Am J Med 1997; 103: 152-162.
7. Tosiello L. Hypomagnesemia and Diabetes Mellitus: A Review of Clinical Implications. Arch Intern Med 1996; 156: 1143-1148.
8. Paolisso G, Sgambato S, Gambardella A, Pizza G, Tesauro P, Varricchio M, D'Onofrio F. Daily magnesium supplements improve glucose handling in elderly subjects. Am J Clin Nutr 1992; 55: 1161-1167.
9. Nadler JL, Buchanan T, Natarajan R, Antonipillai I, Bergman R, Rude R. Magnesium deficiency produces insulin resistance and increased thromboxane synthesis. Hypertension 1993; 21: 1024-1029.
10. Weglicki WB, Mak IT, Kramer JH, Dickens BF, Cassidy MM, Stafford RE, Philips TM. Role of free radicals and substance P in magnesium deficiency. Cardiovasc Res 1996; 31: 677-682.
11. Weglicki WB, Phillips TM, Freedman AM, Cassidy MM, Dickens BF. Magnesium-deficiency elevates circulating levels of inflammatory cytokines and endothelin. Mol Cell Biochem 1992; 110: 169-173.
12. Guerrero-Romero F, Rascón-Pacheco RA, Rodríguez-Morán M, de la Pẽna JE, Wacher N. Hypomagnesaemia and risk for metabolic glucose disorders: a 10-year follow-up study. Eur J Clin Invest 2008; 38: 389-96.
13. Guerrero-Romero F, Rodríguez-Morán M. Relationship between serum magnesium levels and C-reactive protein concentration, in non-diabetic, non-hypertensive obese subjects. Int Obes Relat Metab Disord 2002; 26: 469-74.
14. Rodriguez-Morán M, Guerrero-Romero F. Elevated concentrations of TNF-alpha are related to low serum magnesium levels in obese subjects. Magnes Res 2004; 17: 189-96.
15. Guerrero-Romero F, Rodriguez-Moran M. Hypomagnesemia, oxidative stress, inflammation, and metabolic syndrome. Diabetes Metab Res 2006; 22: 471-6.
16. Kramer JH, Spurney C, Iantorno M, Tziros C, Mak IT, Tejero-Taldo MI, Chmielinska JJ, Komarov AM, Weglicki WB. Neurogenic Inflammation and Cardiac Dysfunction Due to Hypomagnesemia. AmJ Med Sci 2009; 338: 22-7.
17. Ho AS, Moore KW. Interleukin-10 and its receptor. Ther Immunol 1994; 1: 173-85.
18. Avdiushko R, Hongo D, Lake-Bullock H, Kaplan A, Cohen D. IL-10 receptor dysfunction in macrophages during chronic inflammation. J Leukoc Biol 2001; 70: 624-32.
19. Guerrero-Romero F, Tamez-Perez HE, González-González G, Salinas-Martínez AM, Montes-Villarreal J, Trevĩ no-Ortiz JH, Rodríguez-Morán M. Oral Magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab 2004; 30: 253-8.
20. 2+ in etiology of diabetic complications. Diabetes 1992; 41: 35.
21. Katircioglu SF, Ulus AT, Saritas Z, Gökce P. Effects of ATP-MgCl2 administration in hypovolemic dogs. Panminerva Med 1999; 41: 323-30.
22. Shils ME. Experimental production of magnesium deficiency in man. Ann N Y Acad Sci 1969; 162: 847-55.
23. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-7.
24. Mejía-Aranguré JM, Fajardo-Gutierrez A, Gómez-Delgado A, Cuevas-Uriostegui ML, Hernández Hernández DM, Garduñno-Espinoza J, Navarrete-Navarro S, Velázquez-Pérez L, Martínez-arcía M.C. El tamãno de la muestra. Un enfoque práctico en la investigación clínica pediátrica. Bol Med Hosp Infant Mex 1995; 52: 381-91.
25. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9.
26. Guerrero-Romero F, Rodríguez-Morán M, Pérez-Fuentes R, Sánchez-Guillén MC, González-Ortiz M, Martínez-Abundis E, Brito-Zurita O, Madero A, Figueroa B, Revilla-Monsalve C, Flores-Martínez SE, Islas-Andrade S, Rascón-Pacheco RA, Cruz M, Sánchez-Corona J. Prediabetes and its relationship with obesity in Mexican adults: The Mexican Diabetes Prevention (MexDiab) Study. Metab Syndr Relat Disord 2008; 6: 15-23.
27. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
28. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997; 43: 52-8.
29. Curiel-García JA, Rodríguez-Morán M, Guerrero-Romero F. Hypomagnesemia and mortality in patients with type 2 diabetes. Magnes Res 2008; 21: 163-6.
30. Almoznino-Sarafian D, Berman S, Mor A, Shteinshnaider M, Gorelik O, Tzur I, Alon I, Modai D, Cohen N. Magnesium and C-reactive protein in heart failure: an anti-inflammatory effect of magnesium administration? Eur J Nutr 2007; 46: 230-7.
31. Malpuech-Brugère C, Rock E, Astier C, Nowacki W, Mazur A, Rayssiguier Y. Exacerbated immune stress response during experimental magnesium deficiency results from abnormal cell calcium homeostasis. Life Sci 1998; 63: 1815-22.
32. Song Y, Ridker PM, Manson JE, Cook NR, Buring JE, Liu S. Magnesium intake, C-reactive protein, and the prevalence of metabolic syndrome in middle-aged and older U. S. women. Diabetes Care 2005; 28: 1438-44.
33. Song Y, Li TY, van Dam RM, Manson JE, Hu FB. Magnesium intake and plasma concentrations of markers of systemic inflammation and endothelial dysfunction in women. Am J Clin Nutr 2007; 85: 1068-74.
34. Chacko SA, Song Y, Nathan L, Tinker L, de Boer IH, Tylavsky F, Wallace R, Liu S. Relations of dietary magnesium intake to biomarkers of inflammation and endothelial dysfunction in an ethnically diverse cohort of postmenopausal women. Diabetes Care 2010; 33: 304-10.
35. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004; 279: 48487-90.